UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(X) Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For Quarterly Period Ended JULY 31, 1999

() Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Transition Period from _____ to ____

Commission File Number 1-8597

THE COOPER COMPANIES, INC. (Exact name of registrant as specified in its charter)

94-2657368

(I.R.S. Employer Identification No.)

6140 Stoneridge Mall Road, Suite 590, Pleasanton, CA 94588 - (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (925) 460-3600

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes X No

Indicate the number of shares outstanding of each of issuer's classes of common stock, as of the latest practicable date.

Common Stock, \$.10 Par Value Class

INDEX

Page No.

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	
	Consolidated Condensed Statements of Income - Three and Nine Months Ended July 31, 1999 and 1998	3
	Consolidated Condensed Balance Sheets - July 31, 1999 and October 31, 1998	4
	Consolidated Condensed Statements of Cash Flows - Nine Months Ended July 31, 1999 and 1998	5
	Consolidated Condensed Statements of Comprehensive Income - Three and Nine Months Ended July 31, 1999 and 1998	6
	Notes to Consolidated Condensed Financial Statements	7
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	Quantitative and Qualitative Disclosure About Market Risk	23
PART II.	OTHER INFORMATION	
Item 6.	Exhibits and Reports on Form 8-K	24
Signature		25
Index of Exh	ibits	26

PART I. FINANCIAL INFORMATION Item 1. Financial Statements THE COOPER COMPANIES, INC. AND SUBSIDIARIES Consolidated Condensed Statements of Income (In thousands, except per share figures) (Unaudited)

Three Months Ended July 31,		Nine Months Ende July 31,	
1999 	1998	1999	1998
\$ 43,404 15,116	\$ 39,709 14,873	\$120,106	\$106,543 39,177
28,288 16,041 398 954	24,836 13,960 512 932	76,400 45,812 1,301 2,866	67,366 40,218 1,511 2,544
10,895	9,432	26,421	23,093
_ 1,322 54	200 1,532 (271)	4,933 125	200 4,454 757
9,627 3,081	7,429 (910)	21,613 7,132	19,196 (1,864)
6,546	8,339	14,481	21,060
- - 	1,835 1,835	129 2,970 3,099	3,590 - 3,590
\$ 6,546	\$ 10,174	\$ 17,580	\$ 24,650
\$ 0.47 \$ 0.47 	\$ 0.56 0.12 \$ 0.68 =======	\$ 1.03 0.22 \$ 1.25 =======	\$ 1.42 0.24 \$ 1.66 ======
\$ 0.46	\$ 0.54 0.12	\$ 1.01 0.22	\$ 1.37 0.23
\$ 0.46	\$ 0.66	\$ 1.23 =======	\$ 1.60
13,973	14,896	14,118	14,859
14,194	15,342	14,318	15,378
	July 1999 \$ 43,404 15,116 28,288 16,041 398 954 10,895 9,627 3,081 9,627 3,081 \$ 4,546 \$ 6,546 \$ 6,546 \$ 0.47 \$ 0.47 \$ 0.47 \$ 0.46 \$ 0.47 \$ 0.46 \$ 0.46 \$ 0.46 \$ 0.46 	July 31, 1999 1998 $15,116$ 14,873 $28,288$ 24,836 16,041 13,960 398 512 954 932 $$	July 31, July 1999 1998 1999 \$ 43,404 \$ 39,709 \$120,106 15,116 14,873 43,706

See accompanying notes.

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Consolidated Condensed Balance Sheets (Unaudited)

	July 31, 1999	October 31, 1998
	(In t.	housands)
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 11,726	\$ 7,333
Trade receivables, net	26,572	24,426
Inventories	34,953	30,349
Deferred tax asset	15,094	15,057
Net assets of discontinued operations		29,206
Other current assets	8,269	9,706
Total current assets	96,614	116,077
Property, plant and equipment, net	38,469	34,234
Goodwill and other intangibles, net	81,527	84,308
Deferred tax asset	57,224	52,754
Other assets	8,135	8,668
	\$281,969	\$296,041
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
	+	
Accounts and notes payable	\$ 9,038	\$ 13,005
Current portion of long-term debt	3,009	6,958
Current portion of long-term debt Accrued income taxes	3,009 13,878	6,958 8,987
Current portion of long-term debt	3,009	6,958
Current portion of long-term debt Accrued income taxes	3,009 13,878 20,676	6,958 8,987 17,751
Current portion of long-term debt Accrued income taxes Other current liabilities Total current liabilities Long-term debt	3,009 13,878 20,676 46,601 56,496	6,958 8,987 17,751 46,701 78,677
Current portion of long-term debt Accrued income taxes Other current liabilities Total current liabilities	3,009 13,878 20,676 46,601 56,496 22,709	6,958 8,987 17,751 46,701 78,677 25,410
Current portion of long-term debt Accrued income taxes Other current liabilities Total current liabilities Long-term debt	3,009 13,878 20,676 46,601 56,496 22,709 125,806	6,958 8,987 17,751 46,701 78,677 25,410 150,788
Current portion of long-term debt Accrued income taxes Other current liabilities Total current liabilities Long-term debt Other noncurrent liabilities Total liabilities	3,009 13,878 20,676 46,601 56,496 22,709	6,958 8,987 17,751 46,701 78,677 25,410
Current portion of long-term debt Accrued income taxes Other current liabilities Total current liabilities Long-term debt Other noncurrent liabilities Total liabilities Contingencies (see Note 7)	3,009 13,878 20,676 46,601 56,496 22,709 125,806	6,958 8,987 17,751 46,701 78,677 25,410 150,788
Current portion of long-term debt Accrued income taxes Other current liabilities Total current liabilities Long-term debt Other noncurrent liabilities Total liabilities	3,009 13,878 20,676 46,601 56,496 22,709 125,806	6,958 8,987 17,751 46,701 78,677 25,410 150,788
Current portion of long-term debt Accrued income taxes Other current liabilities Total current liabilities Long-term debt Other noncurrent liabilities Total liabilities Contingencies (see Note 7) Stockholders' equity:	3,009 13,878 20,676 46,601 56,496 22,709 125,806	6,958 8,987 17,751 46,701 78,677 25,410 150,788
Current portion of long-term debt Accrued income taxes Other current liabilities Total current liabilities Long-term debt Other noncurrent liabilities Total liabilities Contingencies (see Note 7) Stockholders' equity: Common stock, \$.10 par value	3,009 13,878 20,676 46,601 56,496 22,709 125,806 1,494	6,958 8,987 17,751 46,701 78,677 25,410 150,788 1,491 251,167
Current portion of long-term debt Accrued income taxes Other current liabilities Total current liabilities Long-term debt Other noncurrent liabilities Total liabilities Contingencies (see Note 7) Stockholders' equity: Common stock, \$.10 par value Additional paid-in capital	3,009 13,878 20,676 46,601 56,496 22,709 125,806 1,494 251,020	6,958 8,987 17,751 46,701 78,677 25,410 150,788 1,491 251,167 (829)
Current portion of long-term debt Accrued income taxes Other current liabilities Total current liabilities Long-term debt Other noncurrent liabilities Total liabilities Contingencies (see Note 7) Stockholders' equity: Common stock, \$.10 par value Additional paid-in capital Accumulated other comprehensive loss	3,009 13,878 20,676 46,601 56,496 22,709 125,806 1251,020 (1,008) (81,283) (14,060)	6,958 8,987 17,751 46,701 78,677 25,410 150,788 1,491 251,167 (829) (98,583) (7,993)
Current portion of long-term debt Accrued income taxes Other current liabilities Total current liabilities Long-term debt Other noncurrent liabilities Total liabilities Contingencies (see Note 7) Stockholders' equity: Common stock, \$.10 par value Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit	3,009 13,878 20,676 46,601 56,496 22,709 125,806 1,494 251,020 (1,008) (81,283) (14,060) 156,163	6,958 8,987 17,751 46,701 78,677 25,410 150,788 150,788 150,788 (29) (98,583) (7,993) 145,253
Current portion of long-term debt Accrued income taxes Other current liabilities Total current liabilities Long-term debt Other noncurrent liabilities Total liabilities Contingencies (see Note 7) Stockholders' equity: Common stock, \$.10 par value Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Treasury stock at cost	3,009 13,878 20,676 46,601 56,496 22,709 125,806 1251,020 (1,008) (81,283) (14,060)	6,958 8,987 17,751 46,701 78,677 25,410 150,788 150,788 (829) (98,583) (7,993)

See accompanying notes.

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Consolidated Condensed Statements of Cash Flows (In thousands) (Unaudited)

	Ju	nths Ended ly 31,
	1999	1998
Net cash provided by operating activities	\$ 15,289	\$ 2,510
Cash flows from investing activities:		
Acquisitions of businesses	-	(33,836)
Disposition of discontinued operations, net	28,685	-
Costs of disposition	(3,289)	_ (14,599)
Purchases of property, plant and equipment Sale of securities	(7,547) 5,419	(14,599)
Other	(386)	
Net cash provided (used) by investing activities	22,882	(48,435)
Cash flows from financing activities proceeds from (payment of):		
Long-term debt borrowings	8,532	42,691
Long-term debt payments	(33,989)	(5,155)
Purchase of treasury stock	(7,345)	_
Exercise of warrant	948	-
Dividends on common stock	(280)	-
Short-term debt payment	(2,142)	-
Other	186	383
Net cash provided (used) by financing activities	(34,090)	37,919
Effect of exchange rate changes on cash and cash equivalents	312	(184)
Net increase (decrease) in cash and cash equivalents	4,393	(8,190)
Cash and cash equivalents - beginning of period	7,333	18,249
Cash and cash equivalents - end of period	\$ 11,726 =======	\$ 10,059 ======
Supplemental disclosure of noncash investing and financing activities:		
Acquisitions:		
Fair value of assets acquired		\$ 93,044
Less, liabilities assumed and acquisition costs		(29,707)
		\$ 63,337
Funded by:		
Cash payments		\$ 33,836
Issuance of stock and debt		29,501
		\$ 63,337

\$ 63,337 _____

Casn	paym	ents	5			
Issua	ince	of s	tock	and	debt	

See accompanying notes.

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Consolidated Condensed Statements of Comprehensive Income (In thousands) (Unaudited)

	Three Months Ended July 31,		Nine Months Ended July 31,	
	1999	1998	1999	1998
Net income	\$ 6,546	\$10,174	\$17,580	\$24 , 650
Other comprehensive income (loss), net of tax: Foreign currency translation adjustment	136	(410)	(294)	(649)
Comprehensive income	\$ 6,682	\$ 9,764	\$17,286	\$24,001

See accompanying notes.

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Notes to Consolidated Condensed Financial Statements (Unaudited)

Note 1. General

The Cooper Companies, Inc. (the "Company," "Cooper" or "we" and similar pronouns), through its principal subsidiaries, develops, manufactures and markets healthcare products. CooperVision ("CVI") markets a range of contact lenses to correct visual defects, specializing in toric lenses that correct astigmatism. Its leading products are disposable-planned replacement toric and spherical lenses. CVI also markets conventional toric and spherical lenses and lenses for patients with more complex vision disorders. CooperSurgical ("CSI") markets diagnostic products, surgical instruments and accessories to the women's healthcare market.

During interim periods, we follow the accounting policies described in our most recent Form 10-K. Please refer to this and to our Annual Report to Stockholders for the fiscal year ended October 31, 1998, when reviewing this Form 10-Q. The results in this report do not necessarily indicate future results.

The unaudited consolidated condensed financial statements presented in this report contain all adjustments necessary to present fairly Cooper's consolidated financial position as of July 31, 1999 and October 31, 1998, the consolidated results of its operations for the three and nine months ended July 31, 1999 and 1998, and its consolidated cash flows for the nine months ended July 31, 1999 and 1998. Adjustments consist only of normal recurring items except for the \$2.7 million reduction to the deferred tax asset valuation allowance recorded in the first nine months of fiscal 1998, as Management believed that Cooper's future results would continue to improve. Certain reclassifications have been applied to the prior periods' financial statements so they will conform to the current year's presentation. None of these reclassifications had any impact on net income.

We adopted Statement of Financial Accounting Standards ("FAS") No. 130, "Reporting Comprehensive Income" at the beginning of fiscal 1999. We also adopted FAS No. 131 "Reporting for Segments of a Business Enterprise" in fiscal 1999. The Company will provide the comparative information for interim periods required by FAS No. 131 beginning in its first quarter of fiscal 2000.

Note 2. Inventories

	July 31, 1999	October 31, 1998
	(In the	 ousands)
Raw materials Work-in-process Finished goods	\$ 8,854 3,530 22,569	\$ 7,038 2,964 20,347
	\$34,953 =======	\$30,349 =======

Note 3. Long-Term Debt

	July 31, 1999	October 31, 1998
	(In th	nousands)
Promissory notes - Aspect Midland Bank KeyBank line of credit Aspect Vision bank loans Promissory note - Wesley-Jessen Corporation ("W-J") County of Monroe Industrial Development Agency ("COMIDA") Bond	\$23,117 17,444 6,293 100 2,755	\$27,563 17,444 21,800 6,754 574 2,880
Capitalized leases	9,796	8,620
Less current installments	59,505 3,009	85,635 6,958
	\$56,496 =======	\$78,677 ======

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Notes to Consolidated Condensed Financial Statements, Continued (Unaudited)

Note 4. Earnings Per Share ("EPS")

(In thousands, except per share figures)

	Three Months Ended July 31,		-	31,
	1999 	1998	1999 	1998
Income from continuing operations Discontinued operations	\$ 6,546 _ 	\$ 8,339 1,835	\$14,481 3,099	\$21,060 3,590
Net income	\$ 6,546 =======	\$10,174 ======	\$17,580	\$24,650 ======
Basic: Weighted average common shares	13,973	14,896	14,118	14,859 ======
Basic earnings per share: Continuing operations Discontinued operations	\$ 0.47	\$ 0.56 0.12	\$ 1.03 0.22	\$ 1.42 0.24
Basic earnings per share	\$ 0.47	\$ 0.68 ======	\$ 1.25 ======	\$ 1.66 ======
Diluted: Weighted average common shares	13,973	14,896	14,118	14,859
Add dilutive securities: Warrants Options	16 205	58 388	27 173	60 459
Subtotal	221	446	200	519
Denominator for diluted earnings per share	14,194	15,342	14,318	15,378 ======
Diluted earnings per share: Continuing operations Discontinued operations	\$ 0.46	\$ 0.54 0.12	\$ 1.01 0.22	\$ 1.37 0.23
Diluted earnings per share	\$ 0.46	\$ 0.66 ======	\$ 1.23 ======	\$ 1.60 ======

We excluded the following options to purchase Cooper's common stock from the computation of diluted EPS because their exercise prices were above the average market price.

	Three Months Ended July 31,		Nine Months Ended July 31,	
	1999 1998		1999	1998
Number of shares excluded	1,142,500	231,250	1,245,833	20,100
Range of exercise prices	\$23.44 - \$62.21 ===========	\$36.91 - \$40.38	\$20.00 - \$62.21 ========	\$40.38

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Notes to Consolidated Condensed Financial Statements, Continued (Unaudited)

Note 5. Income Taxes

Substantially all of Cooper's valuation allowance against its net deferred tax assets was reversed in fiscal 1998 based on Management's belief that the Company's future results will enable it to utilize the deferred tax assets recorded on its balance sheet.

As a result, the effective tax rate used to record the provision for income taxes of \$7.1 million for the nine months ended July 31, 1999 was approximately 33%. In the third quarter, updated projections indicated that the full year effective tax rate ("ETR") would be about 33%, down one percentage point from the second quarter's estimate. As a result, the ETR for the three-month period ended July 31, 1999 was approximately 32%. The net tax benefit in the 1998 three- and nine-month periods of \$910,000 and \$1.9 million, respectively, included benefits of \$1 million and \$2.7 million, respectively, from reducing the valuation allowance against net deferred tax assets.

Note 6. Discontinued Operations

In the fourth quarter of 1998, Cooper declared Hospital Group of America ("HGA"), its psychiatric services business, a discontinued operation and recorded a charge of \$22.3 million reflecting Management's initial estimate of the ultimate loss to be incurred upon disposition. Prior period financial statements have been restated.

In January 1999, Cooper completed the sale of a portion of HGA for \$5 million in cash and trade receivables. On April 15, 1999, Cooper sold the remainder of HGA to Universal Health Services, Inc. for \$27 million at closing plus up to an additional \$3 million if certain contingent events occur. Cooper recorded gains on disposal of \$1.3 million in the first quarter and \$1.7 million in the second quarter, reflecting adjustments to the loss estimated in 1998.

HGA's patient revenue was \$14.5 million for the three months ended July 31, 1998. For the nine-month period ended July 31, 1998, patient revenue was \$42.2 million and for the same period in 1999, it was \$20.8 million.

Note 7. Contingencies -- Environmental

In 1997, environmental consultants engaged by the Company identified a contained area of groundwater contamination consisting of industrial solvents including trichloroethane (also known as TCA) at one of CVI's sites. In the opinion of counsel, the solvents were released into the ground before the Company acquired the business at that site, and the area containing these chemicals is limited.

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Notes to Consolidated Condensed Financial Statements, Continued (Unaudited)

On April 6, 1999, the Company and the New York Department of Environmental Conservation entered into a voluntary agreement covering the environmental investigation of the site. The investigation is currently underway and will ultimately result in a state-approved mediation. The Company has accrued approximately \$500,000 for that purpose. In the opinion of Management, the cost of remediation will not be material when considering amounts previously accrued.

Note 8. Treasury Stock

In September 1998, Cooper's Board of Directors authorized the purchase of up to one million shares of its common stock. All of these shares have been purchased.

	Shares	Purchase Price
	(In th	ousands)
Purchased and paid for in fiscal 1998 Purchased in the first quarter of fiscal 1999, paid	486	\$ 7 , 993
for in the second quarter of fiscal 1999	125	1,836
Purchased and paid for in the second quarter of fiscal 1999	389	5,509
	1,000	15,338
Reissued in the third quarter of fiscal 1999*	(83)	(1,278)
	917	\$14,060

* Cooper issued 83,333 shares of treasury stock for the exercise of a warrant it issued related to a prior acquisition. Cooper received \$948,000 for this warrant. The balance of \$330,000 was charged against additional paid in capital.

Note 9. Generally Accepted Accounting Principles Issued But Not Adopted

In April 1998, The American Institute of Certified Public Accountants issued Statement of Position 98-5, "Reporting on the Costs of Start-Up Activities" ("SOP"). The SOP broadly defines start-up activities and requires that they be expensed as incurred. It is effective for financial statements for fiscal years beginning after December 15, 1998. Any deferred start-up activities on the balance sheet at the adoption of the SOP are to be expensed as a cumulative effect of a change in accounting principle. Cooper will adopt the SOP as required in the first quarter of fiscal year 2000 and believes that the impact of such adoption on net income will not be materially in excess of \$700,000. The Company's current policy is to defer start-up activities as appropriate and amortize them over 12 months on a straight-line basis.

Note 10. Authorized Shares of Common Stock

At their March 18, 1999 Annual Meeting, Cooper's shareholders approved an increase in the number of authorized shares of its common stock to 40 million.

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Notes to Consolidated Condensed Financial Statements, Concluded (Unaudited)

Note 11. Cash Dividends

On May 20, 1999, Cooper announced that it intends to pay an annual cash dividend on its common stock of 8 cents per share, payable in quarterly installments of 2 cents per share. On July 5, 1999, we paid the first quarterly dividend, and on August 26, 1999, we announced that we will pay the second quarterly installment on October 5, 1999 to stockholders of record on September 15, 1999.

Note numbers refer to "Notes to Consolidated Condensed Financial Statements" beginning on page 7 of this report.

FORWARD-LOOKING STATEMENTS: This Form 10-Q contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 including statements about Cooper's capital resources, anticipated revenue growth, operating results and market conditions. Since the outcome of forward-looking statements is uncertain, risky and, indeed, may not occur, investors should not rely on them to predict the future.

To identify forward-looking statements, look for words like "believes," "expects," "may," "will," "should," "seeks," "approximately," "intends," "plans," "estimates" or "anticipates", and similar words or phrases. Discussions of strategy, plans or intentions often contain forward-looking statements. These necessarily depend on assumptions, data or methods that may be incorrect or imprecise.

Events that could cause actual results and future actions to differ materially from those described by or contemplated in the forward-looking statements include, but are not limited to, major changes in business conditions and the economy, loss of key senior management, major disruptions in the operations of Cooper's manufacturing facilities, new competitors or technologies, significant disruptions caused by third parties failing to address the year 2000 issue or by unforeseen delays in completing our year 2000 compliance program, acquisition integration costs, foreign currency exchange exposure including the potential impact of the Euro, investments in research and development and other start-up projects, dilution to earnings per share from acquisitions or issuing stock, regulatory issues, significant environmental clean-up costs above those already accrued, litigation costs, costs of business divestitures, and other factors described in Cooper's Securities and Exchange Commission filings, including the "Business" section in our Annual Report on Form 10-K for the year ended October 31, 1998.

Cooper cautions investors not to rely unduly on forward-looking statements. They reflect our analysis only on their stated date.

RESULTS OF OPERATIONS

This section focuses on our income statement and compares our operating results from continuing operations for the third fiscal quarter and nine months of 1999 with those for the same periods of 1998. You will find a discussion of our cash flows and our current financial condition beginning on page 19 in the section headed "Capital Resources and Liquidity."

REVENUE: All of Cooper's revenue is generated by our two business units, CooperVision ("CVI") and CooperSurgical ("CSI"):

 $\ensuremath{\mathsf{CVI}}$ markets a broad range of contact lenses primarily in North America and Europe.

CSI markets diagnostic products, surgical instruments and accessories to the women's healthcare market primarily in the United States.

Our consolidated revenue grew \$3.7 million (9%) in the third quarter and \$13.6 million (13%) in the nine-month period:

		Three Months End July 31,	led	1	Nine Months Endeo July 31,	d
	1999	1998	% Incr.	1999	1998	% Incr.
			(\$ in m	illions)		
CVI CSI	\$ 35.9 7.5	\$ 32.5 7.2	11% 4%	\$ 98.4 21.7	\$ 85.8 20.7	15% 5%
	\$ 43.4	\$ 39.7 ======	9%	\$ 120.1	\$ 106.5	13%

CVI REVENUE: CVI's worldwide core business, which we define as all revenue other than original equipment manufacturer ("OEM") sales to other contact lens suppliers, grew 15% in both the three- and nine-month periods:

Segment	Third Quarter 1999	% Total	% Change from Third Quarter 1998	Nine Months 1999	% Total	% Change from Nine Months of 1998
			(\$ In m	illions)		
U.S.	\$22.5	63%	22%	\$59.1	60%	16%
International	11.7	32%	3%	32.5	33%	12%
Core Business	34.2	95%	15%	91.6	93%	15%
OEM	1.7	5%	(36%)	6.8	7%	15%
Total	\$35.9	100%	11%	\$98.4	100%	15%
	=====					

CVI's core product sales in the U.S. grew 22% in the third quarter and 16% through nine months. The market grew an estimated 1% during the first half of the calendar year as indicated by a contact lens industry market research audit for the second calendar quarter. CVI believes that through fiscal nine months, it gained one market share point in the U.S. to 8 percent. International core revenue--sales in countries outside the United States plus exports from the U.S.--grew 3% during the quarter and 12% over the nine-month period a year ago.

Strong sales of toric contact lenses to correct astigmatism, including new products, grew 24% in both fiscal periods and continued to drive CVI's core business sales in the U.S. This is more than three times the growth of that market segment reported in the most recent market audit. We believe that CVI, with a 27% share, is now the leader in this market segment.

CVI's International sales grew 3% in the third quarter and 12% year to date. Our Canadian and Italian businesses both generated strong sales in the third quarter, and the rollout of new products continued in Europe. These include CVI's line of toric lenses, the Frequency Aspheric lens and Frequency 55 UV, which contains an ultra violet light blocking agent. In Japan, CVI's partner, Rohto Pharmaceuticals, Inc., launched CVI spherical and toric lenses under the Rohto i.Q trade name. With the exception of the United Kingdom, CVI believes that it is gaining market share in each of the world's top ten contact lens markets.

OEM sales decreased 36% in the third quarter, reducing the nine-month increase to 15%. We expect the current shift away from OEM and toward higher margin branded products to continue.

CSI REVENUE: CSI's third quarter revenue grew 4% and is up 5% year to date. In July, CSI announced that it had agreed with 3M (NYSE: MMM) and Matria Healthcare Inc. (NASDAQ: MATR) to co-market its FemExam pH and Amines Test Card in the United States, and that the American Medical Association had awarded the FemExam Card an additional third party reimbursement code. The FemExam Card is an accurate, convenient point of care diagnostic test used to help determine if a vaginal infection is bacterial or fungal. In early August, CSI and BioStar, Inc., a Thermo Electron Corporation (NYSE: TMO) subsidiary, agreed to co-market three additional in-office tests for vaginitis. All four tests are being developed under CSI's licensing agreement with Litmus Concepts, Inc., an emerging in vitro diagnostic company. In the United States, vaginitis accounts for about 13 million physician office visits and about 10 million clinic visits.

COST OF SALES/GROSS PROFIT: Gross profit as a percentage of sales ("margin") was as follows:

	Margin % Three Months Ended July 31,		Margin % Nine Months Ended July 31,	
	1999 	1998	1999	1998
CVI CSI Consolidated	67 56 65	64 55 63	65 56 64	65 55 63

CVI's margin continues to improve from the atypically low 60% reported in the fourth quarter of 1998, when it spent about \$1.7 million to improve efficiency, rationalize manufacturing, expand capacity and fill back orders. The 67% margin reported in the third quarter of 1999 is two percentage points higher than the second quarter of 1999 and four points ahead of the first

quarter. Gross profit of \$24.1 million was 15% above 1998's third quarter. The gross profit improvement reflects cost reduction projects begun last year at our U.K. manufacturing site. In addition, capacity constraints have been eliminated, production yields have improved, customer service levels have improved and staffing levels are returning to normal. We believe that continued cost reductions will result in improving margins during the remainder of fiscal 1999 and beyond, aside from any major changes in product mix.

CSI's margins continue to improve, primarily reflecting continued manufacturing efficiencies associated with Marlow and Unimar products. Unless we make a large acquisition of lower-margin products, we anticipate that recently launched and future proprietary products will, after an initial start-up period, drive continued margin improvement at CSI.

SELLING, GENERAL AND ADMINISTRATIVE ("SG&A") EXPENSE:

		Three Months End July 31,	ed	Ni	ne Months Ended July 31,	
	1999	1998	% Incr.	1999	1998	% Incr.
			(\$ in m	illions)		
CVI CSI HQ/Other	\$11.9 2.3 1.8	\$ 9.4 3.0 1.6	28% (25%) 13%	\$34.2 7.1 4.5	\$27.6 7.6 5.0	24% (6%) (10%)
	\$16.0 =====	\$14.0	15%	\$45.8 =====	\$40.2 =====	14%

SG&A expense was up 15% and 14% in the three- and nine-month periods. At CVI, we have been and continue to engage in investment spending in the sales and marketing arena to launch new products worldwide. We expect that this level of spending will decrease going forward, as we realize the benefit of the annuity stream created by adding new astigmatic patients to our wearer base. Conversely, SG&A at CSI has decreased by 25% and 6% in the three- and nine-month periods, respectively, as CSI's investment spending program to launch its new products occurred primarily in 1998's third quarter. Our headquarters costs are down 10% on a year-to-date basis, although up by \$200,000 in the third quarter. We continue to anticipate that headquarters expenses for the full year will be decreased from the fiscal 1998 levels.

RESEARCH AND DEVELOPMENT ("R&D") EXPENSE: We expect that R&D spending will remain at a low percentage of sales because we are focusing on acquiring products that will not require large expenditures of time or money before introduction.

OPERATING INCOME: Operating income improved by \$1.5 million or 16% and \$3.3 million or 14% in the three- and nine-month periods:

		Three Months En July 31,	ded	1	Nine Months Endeo July 31,	1
	1999	1998	Incr.	1999	1998	Incr.
			 (\$ in mi	llions)		
CVI CSI Headquarters	\$11.4 1.3 (1.8)	\$10.7 0.3 (1.6)	\$ 0.7 1.0 (0.2)	\$27.9 3.0 (4.5)	\$26.2 1.9 (5.0)	\$ 1.7 1.1 0.5
nouaquarterte	\$10.9	\$ 9.4	\$ 1.5 ======	\$26.4	\$23.1 =====	\$ 3.3 ======

INTEREST EXPENSE: Interest expense in the third quarter of 1999 of \$1.3 million was down 14% from 1998's third quarter, reflecting debt payments we made at the end of the second quarter with proceeds from the sale of HGA. (See "Risk Management.") On a year-to-date basis, interest expense is up 11% primarily reflecting debt we incurred to fund the acquisition of Aspect, our investment in Litmus Concepts, Inc. and our stock repurchase program. In September 1998, our Board of Directors authorized us to purchase up to one million of our common shares. We have completed the purchase at an average price of \$15.34 per share. About half of the shares were purchased in each of fiscal 1998 and fiscal 1999.

OTHER INCOME, NET: 1998's nine-month period includes a net foreign exchange gain of about \$500,000, which was predominantly driven by a one-time gain of \$850,000 reflecting weakness in the Pound Sterling occurring before we implemented our hedging program. We do not expect transactions resulting in gains of this magnitude to recur. Through July 31, 1999, we have incurred a net foreign exchange loss of \$284,000.

PROVISION FOR INCOME TAXES: In the fourth quarter of fiscal 1998, we recorded a large tax benefit, reflecting the remaining anticipated value of our \$184 million of net operating loss carryforwards ("NOLs"). As a result, in fiscal 1999, we are reporting our provision for income taxes as if we were a taxpayer with no NOLs, based on our estimate of the effective tax rate ("ETR") for the full fiscal year. In the third quarter, updated projections indicated that our full year ETR would be about 33%, down one percentage point from the previous quarter's estimate. As a result, our ETR for the three-month period ended July 31, 1999 was approximately 32%.

We have recently implemented a global tax plan to minimize both the taxes reported in our income statement and the actual taxes we will have to pay once the benefits of our NOLs are fully utilized. Based on a preliminary assessment, we expect to reduce our ETR to approximately 30% over the next several years. This plan could possibly extend the cash flow benefits of the NOLs through 2003, assuming no major acquisitions or large stock issuances. We expect that actual payments for taxes will be about 10% of pretax profits throughout this period.

GAIN ON DISPOSAL OF DISCONTINUED OPERATIONS: In the fourth quarter of fiscal 1998, we declared Hospital Group of America, Inc. ("HGA"), our psychiatric services business, a discontinued operation and recorded a charge of \$22.3 million reflecting our initial estimate of the ultimate loss we would incur upon disposition.

In January 1999, we completed the sale of a portion of HGA for \$5 million in cash and trade receivables. On April 15, 1999, we sold the remainder of HGA to Universal Health Services, Inc. for \$27 million at closing plus up to \$3 million if certain contingent events occur. Through July 31, 1999, we have recorded gains on the disposals of \$3 million, reflecting adjustments to the loss estimated in 1998.

EARNINGS PER SHARE: In fiscal 1998, we accounted for the remaining tax benefits expected from using our NOLS. Beginning in fiscal 1999, therefore, we provide for income taxes rather than reflect tax benefits. Our historical earnings per share is as follows: (See Note 4 for calculations of these amounts.)

	Three Mont July			ths Ended y 31,
	1999	1998 	1999 	1998
Basic: Continuing operations	\$ 0.47	\$ 0.56	\$ 1.03	\$ 1.42
Discontinued operations Earnings per share	\$ 0.47	0.12	0.22	0.24 \$ 1.66
Diluted:				
Continuing operations Discontinued operations	\$ 0.46 	\$ 0.54 0.12	\$ 1.01 0.22	\$ 1.37 0.23
Earnings per share	\$ 0.46	\$ 0.66 ======	\$ 1.23	\$ 1.60 ======

The change in reporting income taxes discussed above causes material inconsistencies when comparing earnings per share for the fiscal 1999 and 1998 periods presented in this report. To present earnings per share on a consistent basis, we have tax effected the 1998 per share amounts that follow on a pro forma basis. Diluted earnings per share from continuing operations for 1999's third quarter increased 59% to 46 cents from the comparable fully taxed pro forma 29 cents for the same period in 1998. The comparable nine-month figures were \$1.01 and 75 cents, an increase of 35%. Results for the 1998 periods reflect a 40% ETR on income from continuing operations before income taxes to arrive at pro forma net income.

CAPITAL RESOURCES & LIQUIDITY

While we continue to grow our business, we are also strengthening our balance sheet:

Cash and cash equivalents has increased 60% to \$11.7 million since the end of fiscal 1998.

Our ratio of debt to equity has decreased from 0.6:1 at the end of fiscal 1998 to 0.4:1 at July 31, 1999.

Debt now represents about 28% of our total capitalization, down from 38% at October 31, 1998.

Our cash/debt picture has trended positively in fiscal 1999 from the end of fiscal 1998:

	Cash	Debt	Debt
		(In millions)	
October 31, 1998	\$ 7.3	\$90.2	\$82.9
July 31, 1999	\$ 11.7	\$62.0	\$50.3

Net

Our diluted cash flow per share, which we define as pretax income from continuing operations plus depreciation and amortization, increased 24 cents, to 81 cents in the third quarter and 36 cents, to \$1.90 for the nine-month period.

In fiscal 1998 and in the first half of 1999, we invested in the expansion of both our U.K. and our U.S. manufacturing capacity, and we continue through the third quarter of 1999 to invest significantly in sales and marketing costs to launch new products. We expect that our sales will continue to grow and that the rate of our build of new product inventory will level out and then decrease. We also anticipate that our reduced level of investment in manufacturing capacity will continue.

OPERATING CASH FLOWS: In the first nine months of fiscal 1999, we generated \$15.3 million in cash from operating activities, or six times the \$2.5 million generated in the comparable period last year. Each quarter has been solidly ahead of last year:

	1999	1998
	(In mil)	lions)
Q1	\$ (3.4)	\$ (7.0)
Q2	9.2	3.2
Q3	9.5	6.3
Nine months	\$15.3	\$ 2.5
	=====	

The increase primarily reflects improved operating results plus the fact that our investment in inventory and receivables, while continuing to increase, is doing so at a slower rate. Pending a large acquisition or similar transaction that could temporarily skew our results, we expect to generate positive cash flow from operating activities each quarter other than our first quarter. Historically, we have experienced negative operating cash flow in our first quarter due to the timing of payments to settle disputes, inventory builds and bonus payments. Going forward, we expect that cash flows from operating activities will be sufficient to fund both our operating needs and capital expenditure requirements.

INVESTING CASH FLOWS: Our investing cash flows have swung dramatically from an outflow of \$48.4 million to an inflow of \$22.9 million. In addition, we spent approximately \$7.3 million in fiscal 1999 to repurchase shares of our common stock (see Note 8). Approximately \$7 million of this change reflects reduced capital spending on manufacturing capacity, as we have now balanced our supply and demand for contact lenses and are no longer manufacturing constrained. As a result, our capital expenditures have decreased to \$7.5 million this year vs. \$14.6 million in the first nine months of 1998. The balance of the difference is associated with one-time transactions: In 1998, we spent a total of \$33.8 million to acquire Aspect and two smaller acquisitions. In the current year, we received cash of \$25.4 million net of costs from our disposition of HGA.

FINANCING CASH FLOWS: Whereas in 1998 we borrowed money to fund the Aspect acquisition, in 1999 we paid a large portion back upon our disposition of HGA. Accordingly, our cash flows from financing activities were a net reduction of \$34.1 million this year and a net increase of \$37.9 million last year.

OUTLOOK: We believe that cash on hand of \$11.7 million plus cash generated from operating activities will fund future operations, including capital expenditures and pay cash dividends (see Note 11). We may need additional funds for acquisitions and other strategic alliances. At July 31, 1999, we had over \$25 million available under the KeyBank line of credit, and we anticipate that additional financing would be available as required.

RISK MANAGEMENT: We are exposed to risks caused by changes in foreign exchange, principally Pound Sterling denominated debt and from operations in foreign currencies. We have hedged most of this risk by entering into contracts to buy Sterling forward. We are also exposed to risks associated with changes in interest rates, as the interest rate on certain of our debt varies with the London Interbank Offered Rate. We have protected ourselves against most of this risk by entering into agreements to swap most of our variable rate debt for fixed rate debt.

Proceeds from the sale of HGA were used to pay down debt carrying an average interest rate of approximately 7%. Total debt was reduced to \$62 million at July 31, 1999 from \$90.2 million at October 31, 1998:

	July 31, 1999	October 31, 1998
	(In mi	llions)
Short term Long term	\$ 5.5 56.5	\$ 11.5 78.7
Total	\$ 62.0 ======	\$ 90.2 ======

On an annualized basis the debt reduction would result in a decrease in interest expense of approximately \$2 million, assuming we do not raise debt for other purposes.

YEAR 2000: The year 2000 ("Y2K") problem exists today because programmers who developed computer systems and applications over the past few decades used two digit date codes to designate the year. This creates a problem in the year 2000 in that many systems will recognize "00" as the year 1900 rather than 2000 and, if not fixed, may abort or produce erroneous data once the year 2000 arrives.

We have completed an in-depth review of the financial and operational systems at each of our business units and have implemented a Y2K compliance program to confirm that all critical business systems, software and equipment that consider and process date-related information will continue to function properly after December 31, 1999. Final testing of critical systems has begun, and we anticipate that our Y2K project will be substantially completed by September 30, 1999.

We initiated compliance programs in 1995 to modify our proprietary software, and many of the required changes have been completed. Recently purchased software requires only minimal modification, and we are endeavoring to ensure that any new software purchased will be Y2K compliant. We have used both internal and external resources to reprogram, or replace, and test our software for Y2K modifications.

We have assigned a key employee at each of our major operations to be responsible for Y2K compliance. We have also appointed a Y2K Compliance Officer who reports to the Board of Directors on program status.

We have experienced significant growth in the past three years and are beginning implementation of a broad-based Enterprise Resource Planning ("ERP") system throughout major CVI operations in the U.S. and the U.K. The new ERP system will be Y2K compliant. In any event, as part of our contingency plan, CVI will take all necessary and reasonable steps to ensure that all of its existing systems are Y2K compliant prior to the conversion to the new system. In addition, at Aspect Vision plans are in place to build additional contact lens inventory prior to 2000 to assure uninterrupted flow of products to customers.

We have or are currently working to ensure Y2K compliance of all business systems and do not anticipate material Y2K problems. We also have or are currently communicating with vendors to determine their Y2K compliance and to date are not aware of any third party Y2K issues that could materially affect operations.

We will continue to devote adequate resources to address Y2K issues. We cannot, however, assure that systems and products do not contain undetected Y2K problems, that we will not experience operating difficulties as a result of Y2K issues or that new systems will be implemented in time to avoid the probability of Y2K problems. Further, we cannot assure that our assessment of suppliers and vendors will be accurate or that all suppliers and vendors will provide sufficient information to enable us to make such assessment.

We have developed contingency plans to identify and mitigate potential Y2K problems and assess their impact on operations. These plans are designed to protect our assets, continue safe operations and allow any interrupted operations to resume in a timely fashion. However, contingency planning for Y2K issues is complicated by possible multiple and simultaneous incidents, which could significantly delay our efforts to respond and resume normal business. Such incidents may be outside our control, if, for example, third parties providing goods and/or services critical to our operations do not successfully address their own material Y2K problems.

Based on our Y2K assessment, we anticipate that the cost to upgrade or replace our programs, systems and equipment will not materially affect our financial position. We currently estimate that expenditures of approximately \$500,000, including capital, will be required for us to be Y2K compliant. Approximately \$380,000 has been expended to date.

TRADEMARKS: The following trademarks italicized in this report are owned by, licensed to or distributed by The Cooper Companies, Inc., its subsidiaries or affiliates: FemExam'r' TestCard System'TM', Hyskon'r', Marlow'TM' and Unimar'r'.

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Item 3. Quantitative and Qualitative Disclosure About Market Risk

See Capital Resources and Liquidity under "Risk Management" in Item 2 of this report for a discussion of debt paid down in fiscal 1999.

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits.

Exhibit Number 	Description
11*	Calculation of Earnings Per Share.
27	Financial Data Schedule for the nine months ended July 31, 1999.

- * The information called for in this exhibit is provided in Footnote 4 to the Consolidated Condensed Financial Statements in this report.
 - (b) The Company filed the following reports on Form 8-K during the period May 1, 1999 to July 31, 1999.

Date of Report	Item Reported
April 29, 1999	Item 5. Other Events.
May 27, 1999	Item 5. Other Events.
July 13, 1999	Item 5. Other Events.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

The Cooper Companies, Inc.

(Registrant)

Date: September 13, 1999

/s/ Robert S. Weiss

Executive Vice President, Treasurer and Chief Financial Officer

Index of Exhibits

Exhibit No.

Page No.

11* 27

Calculation of Earnings Per Share. Financial Data Schedule.

* The information called for in this exhibit is provided in Footnote 4 to the Consolidated Condensed Financial Statements in this report.

STATEMENT OF DIFFERENCES

```
9-MOS

OCT-31-1999

NOV-01-1998

JUL-31-1999

11,726

0

27,650

1,078

34,953

96,614

51,444

12,975

281,969

46,601

56,496

1,494

0

0

154,669

281,969

120,106

43,706

0

43,706

0

43,706

0

0

4,933

21,613

7,132

14,481

3,099

0

0

17,580

1.23
```